1921
Volume 83, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non–life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exorbitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2010.10-0156
2010-08-05
2020-10-31
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/2/357.html?itemId=/content/journals/10.4269/ajtmh.2010.10-0156&mimeType=html&fmt=ahah

References

  1. WHO, 2009. Communicable Diseases, Kala-Azar status in SEA Region. Available at: http://www.searo.who.int/en/section10/section2163_11668.htm. Accessed December 16, 2009.
    [Google Scholar]
  2. Desjeux P, 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305318.[Crossref]
    [Google Scholar]
  3. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S, 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect Dis 5: 763774.[Crossref]
    [Google Scholar]
  4. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 11041107.[Crossref]
    [Google Scholar]
  5. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D, 1999. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani . J Infect Dis 180: 564567.[Crossref]
    [Google Scholar]
  6. Sundar S, Singh VP, Sharma S, Makharia MK, Murry HW, 1997. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 176: 11171119.[Crossref]
    [Google Scholar]
  7. Thakur CP, Narayan S, Ranjan A, 2004. Epidemiological, clinical and pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 120: 166172.
    [Google Scholar]
  8. Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK, 2005. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar. Natl Med J India 18: 131133.
    [Google Scholar]
  9. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, Narain S, Roy RK, 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 92: 561569.[Crossref]
    [Google Scholar]
  10. Ahasan HA, Chowdhury MA, Azhar MA, Rafiqueuddin AK, Azad KA, 1996. Deaths in visceral leishmaniasis (kala-azar) during treatment. Med J Malaysia 51: 2932.
    [Google Scholar]
  11. Sindermann H, Engel J, 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S17S20.[Crossref]
    [Google Scholar]
  12. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 17391746.[Crossref]
    [Google Scholar]
  13. Sundar S, Murray HW, 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83: 394395.
    [Google Scholar]
  14. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 25712581.[Crossref]
    [Google Scholar]
  15. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 38: 377383.[Crossref]
    [Google Scholar]
  16. WHO, 2005. Report of a WHO Informal Consultation on Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis. Available at: http://www.who.int/neglected_diseases/resources/AmBisomeReport.pdf. Accessed December 17, 2009.
    [Google Scholar]
  17. Sundar S, Rai M, 2002. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 15: 593598.[Crossref]
    [Google Scholar]
  18. Rosenthal E, Marty P, 2003. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 49: 6168.[Crossref]
    [Google Scholar]
  19. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323: 419422.[Crossref]
    [Google Scholar]
  20. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800804.[Crossref]
    [Google Scholar]
  21. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P, 1996. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomised dose finding study. Trans R Soc Trop Med Hyg 90: 319322.[Crossref]
    [Google Scholar]
  22. Thakur CP, 2001. A single dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 6770.[Crossref]
    [Google Scholar]
  23. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R, 2002. Low dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143146.
    [Google Scholar]
  24. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504512.[Crossref]
    [Google Scholar]
  25. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917924.[Crossref]
    [Google Scholar]
  26. Collin S, Davidson R, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C, 2004. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38: 612619.[Crossref]
    [Google Scholar]
  27. Centres for Disease Control and Prevention, 2009. The SAS Program for the CDC Growth Charts. Available at: http://www.cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm. Accessed April 14, 2009.
    [Google Scholar]
  28. National Cancer Institute Cancer Therapy Evaluation Program, 2003. Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) DCTD, NCI, NIH, DHHS. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed December 21, 2009.
    [Google Scholar]
  29. Astellas Pharma US, Inc., 2007. AmBisome (Amphotericin B) Liposome for Injection. Available at: http://www.ambisome.com/index2.php?section=about&page=trials. Accessed March 19, 2009.
    [Google Scholar]
  30. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C, 2004. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 364: 789790.[Crossref]
    [Google Scholar]
  31. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, Asumu PN, Simarro PP, Burri C, 2005. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (impamel II). J Infect Dis 191: 19221931.[Crossref]
    [Google Scholar]
  32. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G, 2007. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1: e64.[Crossref]
    [Google Scholar]
  33. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 2532.
    [Google Scholar]
  34. Adler-Moore J, Proffitt RT, 2002. Ambisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49 (Suppl 1): 2130.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.10-0156
Loading
/content/journals/10.4269/ajtmh.2010.10-0156
Loading

Data & Media loading...

  • Received : 12 Mar 2010
  • Accepted : 06 May 2010
  • Published online : 05 Aug 2010
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error